Effect of Beta Glucan on White Blood Cell Counts and Serum Levels of IL-4 and IL-12 in Women with Breast Cancer Undergoing Chemotherapy: A Randomized Double-Blind Placebo-Controlled Clinical Trial

被引：24
作者：
Ostadrahimi, Alireza [1 ]
Ziaei, Jamal Eivazi [2 ]
Esfahani, Ali [2 ]
Jafarabadi, Mohammad Asghari [3 ]
Movassaghpourakbari, Aliakbar [2 ]
Farrin, Nazila [4 ]
机构：
[1] Tabriz Univ Med Sci, Nutr Res Ctr, Fac Nutr, Tabriz, Iran
[2] Tabriz Univ Med Sci, Hematol & Oncol Res Ctr, Tabriz, Iran
[3] Tabriz Univ Med Sci, Fac Hlth, Rd Traff Injury Prevent Res Ctr, Tabriz, Iran
[4] Tabriz Univ Med Sci, Student Res Comm, Fac Nutr, Tabriz, Iran
来源：
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION | 2014年 / 15卷 / 14期
关键词：
Beta glucan; white blood cell; IL-4; IL-12; breast cancer; chemotherapy;
D O I：
10.7314/APJCP.2014.15.14.5733
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: Breast cancer is the most common female malignancy in the world. Beta glucan can be a hematopoietic and an immune modulator agent in cancer patients. The aim of this trial was to determine the effect of beta glucan on white blood cell counts and serum levels of IL-4 and IL-12 in women with breast cancer undergoing chemotherapy. Materials and Methods: This randomized double-blind placebo-controlled clinical trial was conducted on 30 women with breast carcinoma aged 28-65 years. The eligible participants were randomly assigned to intervention (n=15) or placebo (n=15) groups using a block randomization procedure with matching based on age, course of chemotherapy and menopause status. Patients in the intervention group received two 10-mg capsules of soluble 1-3, 1-6, D-beta glucan daily and the control group receiving placebo during 21 days, the interval between two courses of chemotherapy. White blood cells, neuthrophil, lymphocyte and monocyte counts as well as serum levels of IL-4 and IL-12 were measured at baseline and at the end of the study as primary outcomes of the study. Results: In both groups white blood cell counts decreased after 21 days of the intervention, however in the beta glucan group, WBC was less decreased non significantly than the placebo group. At the end of the study, the change in the serum level of IL-4 in the beta glucan group in comparison with the placebo group was statistically significant (p=0.001). The serum level of IL-12 in the beta glucan group statistically increased (p=0.03) and comparison between two groups at the end of the study was significant after adjusting for baseline values and covariates (p=0.007). Conclusions: The findings suggest that beta glucan can be useful as a complementary or adjuvant therapy and immunomodulary agent in breast cancer patients in combination with cancer therapies, but further studies are needed for confirmation.
引用
收藏
页码：5733 / 5739
页数：7
相关论文
共 39 条
  • [1] Akramiene D., Kondrotas A., Didziapetriene J., Kevelaitis E., Effects of beta-glucans on the immune system, Medicina, 43, pp. 597-606, (2007)
  • [2] Asharijafarabadi M., Mohammadi S., Statistical series: summarizing and displaying data, J Diabetes Lipid Dis, 12, pp. 83-100, (2013)
  • [3] Baran J., Allendorf D.J., Hong F., Ross G.D., Oral beta-glucan adjuvant therapy converts nonprotective Th2 response to protective Thl cell-mediated immune response in mammary tumor-bearing mice, Folia HistochemCytobiol, 45, pp. 107-114, (2007)
  • [4] Brown G.D., Taylor P.R., Reid D.M., Et al., Dectin-1 is a major beta-glucan receptor on macrophages, J Exp Med, 196, pp. 407-412, (2002)
  • [5] Budak F., Goral G., Oral H.B., Saccharomyces cerevisiae beta-glucan induces interferon-gamma production in human t cells via IL-12, Turk J Immunol, 13, pp. 21-26, (2008)
  • [6] Chan G.C., Chan W.K., Sze D.M., The effects of beta-glucan on human immune and cancer cells, JHematol Oncol, 2, (2009)
  • [7] Cramer D.E., Wagner S., Li B., Et al., Mobilization of hematopoietic progenitor cells by yeast-derived (3-glucan requires activation of matrix metalloproteinase 9, Stem Cells, 26, pp. 1231-1240, (2008)
  • [8] Demir G., Klein H.O., Mandel-Molinas N., Tuzuner N., Beta glucan induces proliferation and activation of monocytes in peripheral blood of patients with advanced breast cancer, Int Immunopharmacol, 7, pp. 113-116, (2007)
  • [9] DeNardo D.G., Coussens L.M., Inflammation and breast cancer Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression, Breast Cancer Res, 9, (2007)
  • [10] Foa R., Guarini A., Gansbacher B., IL2 treatment for cancer: from biology to gene therapy, Br J Cancer, 66, pp. 992-998, (1992)
1234